| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 07/18/2006 | US7078487 Polynucleotides encoding the zebrafish PTH1R (parthyroid hormone like protein) receptor |
| 07/18/2006 | US7078416 Polypeptides |
| 07/18/2006 | US7078217 Aggrecanase molecules |
| 07/18/2006 | US7078206 for drug screening enzyme inhibitors; by isolating DNA from a patient, amplifying exons by polymerase chain reaction (PCR) and detecting the presence of DNA sequence variation; genetic engineering |
| 07/18/2006 | US7078193 Pathogenic Escherichia coli associated protein espA |
| 07/18/2006 | US7078191 Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
| 07/18/2006 | US7078186 Nucleotide sequences coding polypeptide for use in the prevention, diagnosis and treatment of tumor disorders |
| 07/18/2006 | US7078179 High speed detection, isolation of cells; binding to antibodies; fluorescence classification; purification of antibody from egg yolk |
| 07/18/2006 | US7078175 Antibodies for apoptosis EI24 protein and methods of use |
| 07/18/2006 | US7078173 Assays and therapies for latent viral infection |
| 07/18/2006 | US7078166 Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| 07/18/2006 | US7078042 Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| 07/18/2006 | US7078036 Modulation of cholesteryl ester transfer protein (CETP) activity |
| 07/18/2006 | CA2307317C Tumor rejection antigen precursors, tumor rejecti0n antigens and uses thereof |
| 07/18/2006 | CA2195556C Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype |
| 07/13/2006 | WO2006074451A2 Targeted chimeric molecules for cancer therapy |
| 07/13/2006 | WO2006074418A2 Ovr110 antibody compositions and methods of use |
| 07/13/2006 | WO2006074389A2 Four-helical bundle protein zsig99 |
| 07/13/2006 | WO2006074228A1 Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 ) |
| 07/13/2006 | WO2006074199A1 Immunoglobulin chimeric monomer-dimer hybrids |
| 07/13/2006 | WO2006074071A1 Framework residue substituted humanized col-1 antibodies and their use |
| 07/13/2006 | WO2006073982A2 Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein |
| 07/13/2006 | WO2006073748A2 Antibodies against antigen presenting cells and uses thereof |
| 07/13/2006 | WO2006073493A2 Vaccine conjugates comprising a monoclonal antibody binding to human dentritic cells and beta human chronic gonadotropin |
| 07/13/2006 | WO2006073133A1 Novel tannase gene and protein thereof |
| 07/13/2006 | WO2006073119A1 Polypeptide and use of the same |
| 07/13/2006 | WO2006072803A2 Antibody |
| 07/13/2006 | WO2006072626A1 Kir-binding agents and methods of use thereof |
| 07/13/2006 | WO2006072620A1 Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| 07/13/2006 | WO2006072601A2 THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31 |
| 07/13/2006 | WO2006072564A1 Antibodies against il-13 receptor alpha 1 and uses thereof |
| 07/13/2006 | WO2006072166A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/13/2006 | WO2006050949A3 Superagonistic anti-cd28 antibody |
| 07/13/2006 | WO2006042149A3 Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides |
| 07/13/2006 | WO2006009525A3 P. aeruginosa mucoid exopolysaccharide specific binding peptides |
| 07/13/2006 | WO2005117974B1 Cancer treatment method by inhibiting mage gene expression or function |
| 07/13/2006 | WO2005104754A3 System and method for identifying complex patterns of amino acids |
| 07/13/2006 | WO2005100403A3 Antibodies to erythropoietin receptor and uses thereof |
| 07/13/2006 | WO2005081749A3 Neutralizing human antibodies to anthraxtoxin |
| 07/13/2006 | WO2005077416A3 Lipid rafts and clostridial toxins |
| 07/13/2006 | WO2005032454A3 Anti-muc-1 single chain antibodies for tumor targeting |
| 07/13/2006 | WO2004092197A8 Amyloid-specific peptides and uses thereof |
| 07/13/2006 | WO2003083073A3 Binding assay employing gpcr 192 |
| 07/13/2006 | US20060155113 Replication protein |
| 07/13/2006 | US20060155111 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 07/13/2006 | US20060155109 agonist; a memory function improving agent, appetite regulator; an uterine, renal, testis, spleen, heart, prostatic or skeletal muscle function improving agent; antiobesity agent, antiabetic |
| 07/13/2006 | US20060154871 Peptides |
| 07/13/2006 | US20060154858 Canine rankl and methods for preparing and using the same |
| 07/13/2006 | US20060154339 Novel clock gene BMAL2 |
| 07/13/2006 | US20060154335 Novel members of the steroid/thyroid superfamily and uses therefor |
| 07/13/2006 | US20060154334 Method of producing an antibody to epidermal growth factor receptor |
| 07/13/2006 | US20060154321 Using immunoglobulins specific for brain natriuretic peptide to diagnose, classify, stratify and prognose mortality rates in patients with congestive heart failure; using biotin detector and peroxidase-labeled streptavidin reporter |
| 07/13/2006 | US20060154313 Human B7 polypeptide B7-H3A |
| 07/13/2006 | US20060154311 Antibody specifically binding to a fragment of a nuclear matrix protein, BLCA-1 or BLCA-4, present only in cancerous bladder cells; drug conjugates; labeled antibodies; diagnostics; antiproliferative agents |
| 07/13/2006 | US20060154310 Detecting the presence of a prostate cancer cell expressing a protein SGP28; immunoassay |
| 07/13/2006 | US20060154295 Nucleotide sequence which encodes a flavin monooxygenase, the corresponding protein and their uses in the spheres of diagnosis and therapy |
| 07/13/2006 | US20060154294 Interleukin-18 binding proteins, their preparation and use |
| 07/13/2006 | US20060154291 Reagents and methods useful for detecting diseases of the breast |
| 07/13/2006 | US20060154285 Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2) |
| 07/13/2006 | US20060154277 Compositions and methods for diagnosing or treating psoriasis |
| 07/13/2006 | US20060154250 Novel compositions and methods in cancer |
| 07/13/2006 | US20060154244 Novel g-protein coupled receptor |
| 07/13/2006 | US20060154243 Antigenic peptides of SARS coronavirus and uses thereof |
| 07/13/2006 | US20060153922 Light induced immobilisation |
| 07/13/2006 | US20060153863 Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's |
| 07/13/2006 | US20060153862 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses |
| 07/13/2006 | US20060153856 Monoclonal antibodies that bind Pseudomona mucoid heteropolysaccharides; used in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis); enhance opsonophagocytic killing of multiple mucoid strains |
| 07/13/2006 | US20060153855 Prevention and treatment of the porcine reproductive and respiratory syndrome (PRRS) |
| 07/13/2006 | US20060153854 Antibody induced cell membrane wounding |
| 07/13/2006 | US20060153852 Novel human Jak2 kinase |
| 07/13/2006 | US20060153851 CLASP proteins |
| 07/13/2006 | US20060153850 Antibodies to M-CSF |
| 07/13/2006 | US20060153849 Methods of treatment with an antibody that suppresses growth differentiation factor-14 activity |
| 07/13/2006 | US20060153846 Formulation of human antibodies for treating tnf-alpha associated disorders |
| 07/13/2006 | US20060153845 Method for correcting immune respones and medical agent |
| 07/13/2006 | US20060153843 Method of immunomodulation |
| 07/13/2006 | US20060153842 Immunosuppressive combination and its use in the treatment or prophylaxis or insulin-producing cell graft rejection |
| 07/13/2006 | US20060153841 Nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro |
| 07/13/2006 | US20060153839 Production of bispecific molecules using polyethylene glycol linkers |
| 07/13/2006 | US20060153838 Fc region variants |
| 07/13/2006 | US20060153837 Treating autoimmune diseases with humanized anti-CD401 antibodies |
| 07/13/2006 | US20060153836 Using monoclonal antibody specific for kidney injury-molecule-1 (KIM-1) to diagnose, prevent and treat cell proliferative and kidney disorders; immunotherapeutics |
| 07/13/2006 | US20060153833 Anti hepatitis C virus antibody and uses thereof |
| 07/13/2006 | US20060153802 Mammalian chemokine reagents |
| 07/13/2006 | US20060153800 DNA immunization with recombinase/transposase |
| 07/13/2006 | US20060153770 Method of treating tumors |
| 07/13/2006 | DE102004063494A1 Antikörper Antibody |
| 07/13/2006 | CA2614946A1 Biomarkers for melanoma |
| 07/13/2006 | CA2595112A1 Polypeptides that bind br3 and uses thereof |
| 07/13/2006 | CA2594356A1 Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| 07/13/2006 | CA2594233A1 Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 ) |
| 07/13/2006 | CA2594143A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/13/2006 | CA2594023A1 Igf-i fusion polypeptides and therapeutic uses thereof |
| 07/13/2006 | CA2593693A1 Framework residue substituted humanized col-1 antibodies and their use |
| 07/13/2006 | CA2593648A1 Targeted chimeric molecules for cancer therapy |
| 07/13/2006 | CA2593212A1 Cripto binding molecules |
| 07/13/2006 | CA2592614A1 Antibodies against il-13 receptor alpha 1 and uses thereof |
| 07/13/2006 | CA2591138A1 Antibodies against antigen presenting cells and uses thereof |
| 07/13/2006 | CA2575248A1 Antibody vaccine conjugates and uses therefor |
| 07/13/2006 | CA2564296A1 Antagonist anti-cd40 monoclonal antibodies and methods for their use |